Dermatologist
Professor, Oncologist
Dr. Hossein Taghizadeh is a highly regarded Austrian specialist in internal medicine, hematology, and medical oncology, known for his compassionate approach and commitment to personalized cancer care. With extensive experience in treating solid tumors and blood cancers, he represents a new generation of oncologists who integrate scientific progress with empathy and precision.
He studied medicine at the Medical University of Vienna, graduating in 2016, and began his residency in internal medicine and oncology shortly thereafter. His academic and clinical training at leading Austrian cancer centers equipped him with deep expertise in systemic cancer therapy, hematologic diseases, and palliative medicine.
2010–2016 – Studied medicine at the Medical University of Vienna.
2018 – Began residency in internal medicine and medical oncology, focusing on individualized treatment strategies.
2020s – Specialized in solid tumors, hematologic malignancies, and targeted therapy, contributing to multidisciplinary oncology care.
Today – Practices as an oncologist at Oncodoc and Wiener Privatklinik, providing diagnostics, systemic treatment, and follow-up for patients with gastrointestinal, urogenital, and hematologic cancers.
Dr. Taghizadeh’s clinical interests include gastrointestinal tumors, pancreatic and biliary cancers, genitourinary malignancies, and hematologic neoplasms. He works with advanced diagnostic tools and modern systemic therapies, including chemotherapy, targeted therapy, and immunotherapy.
Known for his calm professionalism, integrity, and patient-centered communication, Dr. Taghizadeh places great emphasis on evidence-based medicine and emotional support throughout the treatment journey. His work reflects a modern, holistic approach to oncology — one that values both medical excellence and the human experience behind every diagnosis.
Coping with gastrointestinal and lung cancer without chemotherapy. Specialists at the Tel Aviv Sourasky Clinic (Ichilov) use an ultra-modern innovative method to combat neuroendocrine tumors. It is based on radionuclide therapy with the radioisotope Lutetium 177 (Lutetium-177). This innovation is a real breakthrough in oncotherapy, because in recent decades the number of cases of this type of cancer has been rapidly growing.
This method is completely new in the world. Today it exists only in Israel, Germany and Sweden.
Its essence is in the use of a new radiopharmaceutical - Lutetium 177 PRRT. The drug is administered intravenously at intervals of 7-8 weeks. With the help of Lutetium, cancer cells are destroyed selectively, without affecting healthy tissues of the body. That is, this method of treatment can literally be called "local radiation therapy". In addition, the drug does not have a toxic effect on the bone marrow and kidneys, destroying the tumor from the inside.
In addition, the use of this method allows patients to avoid severe side effects of chemotherapy, such as vomiting, nausea, pain, alopecia, weakness. It is also important that the treatment is carried out by a special group of medical specialists. Among them: leading doctors, nurses and medical physicists!
All of them work under the supervision of Dr. Inna Ospovat, a leading specialist in the nuclear therapy department at the Ichilov Clinic.
Education
2000-1994 Faculty of Medicine in Vitebsk, Belarus.
Specialization
2003 - 2011 - specialization in oncology and radiation therapy at the Hadassah University Hospital in Jerusalem.
Recognized experience
Oncology and radiation therapy
Additional education
2015 - PMH University Hospital (Totonto) Childhood irradiation and head and neck tumors
Attending conferences
About 10 presentations at medical conferences
Trade union membership
Dr. Christiane Thallinger is an Austrian dermatologist and venereologist. She focuses on skin cancer and oncologic dermatology. She began her medical career in 1999. She completed dermatology training at the Medical University of Vienna. She later served as a senior physician in its Department of Dermatology.
Her expertise includes diagnosis and treatment of melanoma, basal cell carcinoma, and squamous cell carcinoma. She performs dermatosurgery, cryotherapy, and photodynamic therapy. She also manages skin side effects caused by cancer treatment.
She is active in patient care and academic research. She is recognized for her patient-centered approach and for advancing dermatologic oncology in Austria.
Education/Residency:
Dr. Tatyana Rabin's research interests include:
Methods of destruction of malignant neoplasms by heating with the help of ultrasonic waves, research into the use of brachytherapy in the treatment of oncogynecological diseases,
study of the mechanisms of response at the molecular level of prostate tumor cells to radiotherapy;
clinical studies of oncomammology, oncopulmonology, ocular lymphoma.
Dr. Rabin is investigating the molecular mechanisms by which prostate cancer cells respond to radiation therapy. This research is being conducted in collaboration with the Weizmann Institute of Science.
In addition, Dr. Rabin has been involved in clinical research in the areas of breast cancer, lung cancer, and ocular lymphoma.
Dr. Rabin is currently coordinating a new and unique study at Sheba Hospital that is investigating a method of treating cancerous tumors using MRI-guided ultrasound waves. This method involves raising the tumor's temperature to a certain level and then destroying it.
Awards:
Dr. Tatyana Rabin was recognized as the best hospital employee for 2007.
Experience and participation in scientific research:
Membership in medical societies :
Education
Faculty of Medicine: Sackler Faculty of Medicine, Tel Aviv University
Specialization
Institute of Oncology, Davydov Center, Beilinson Hospital
Recognized experience
Medical Oncology and Radiation Therapy
Additional education
Department of Radiation Therapy, Duke University Medical Center, USA
Clinical experience
Attending conferences
About 15 professional publications
Trade union membership
Areas of special interest and activities
Cerebral metastases and primary brain tumors, head and neck tumors, radiation therapy and radiosurgery
Dr. Sternheim Amir is an experienced orthopaedic surgeon. He specializes in orthopaedic oncology, joint replacement, and complex hip and knee reconstruction. He is known for using advanced 3D technology and computer-assisted methods. These tools help him plan surgeries with high precision, especially for predicting femur fractures in patients with metastatic disease.
Dr. Amir has published many research papers and has spoken at major medical conferences. His main interests are sarcoma and metastatic bone cancer. He has received several awards, such as the Outstanding Resident Award at Tel-Aviv Medical Center. He has also earned grants from the Israeli Cancer Society and the University of Toronto. Dr. Amir is an active member of MSTS, CTOS, and ISOLS, which shows his strong reputation in the field.
Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.
Prof. Jack Baniel is a Professor of Urology and Chief of Urology section at Rabin Medical Center, Petach Tikva, Israel. He specializes in the reconstruction of the bladder, robotic prostatectomy, cancer surgeries with preservation of the nerve endings. He has published over 100 scientific articles and is actively involved in research in the field of uro-oncology. He is a graduate of Tel Aviv University and is a member of various professional organizations, including the Israeli Medical Association, the Israeli Association of Urology, the European Association of Urology, the European Organization for Research and Treatment of Cancer (EORTC), and the American Association of Urology.